Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autogene cevumeran + atezolizumab + mFOLFIRINOX versus mFOLFIRINOX in resected pancreatic ductal adenocarcinoma
NL-OMON59712Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Autogene cevumeran + atezolizumab + mFOLFIRINOX with mFOLFIRINOX alone (2 arms). Primary endpoint: Disease-free survival after randomization. Started Nov 2024; status: active, not recruiting.
02
Drugs
autogene cevumeranatezolizumabmFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59712.